Jay-JiguangZhuMDPHD

Neurology • Houston, TX

Neurooncology

Full Professor, Neuro-oncology of Neurosurgery Dept, University of Texas Medical School, Houston

Join to view full profile

Dr. Zhu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zhu's full profile

Already have an account?

Office
UTHealth Neurosciences- Texas Medical Center
6400 Fannin St. Ste 2800, Dept Of Neurosurgery
Houston, TX 77030
Phone+1 713-486-8000

Fax+1 713-795-8104

Education & Training

Massachusetts General HospitalFellowship, Neuro-Oncology, 2003 - 2005
Tufts Medical CenterResidency, Neurology, 2000 - 2003
Berkshire Medical CenterInternship, Internal Medicine, 1999 - 2000
McGill University Faculty of MedicineClass of 1999

Certifications & Licensure

TX State Medical License 2010 - 2025
MA State Medical License 2005 - 2012
American Board of Psychiatry and Neurology Neurology
United Council for Neurologic SubspecialtiesNeuro-oncology

Clinical Trials

131-I-TM-601 Study in Adults With Solid Tumors Start of enrollment: 2006 Aug 01
Completed
Phase 1
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Start of enrollment: 2008 Aug 01
Unknown status
Phase 1, Phase 2
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08
Active, not recruiting
Not Applicable
Roles: Contact
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) Start of enrollment: 2023 Jan 23
Recruiting
Phase 3
Roles: Contact, Principal Investigator
A Prospective Study of a Modified Lumbar Puncture (LP) Procedure That Reduces Post-Lumbar Puncture Headaches (PLPH) in Patients Start of enrollment: 2023 Nov 08
Recruiting
Not Applicable
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

40 citations
NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways
Naze G. Avci, Sadaf Ebrahimzadeh-Pustchi, Yasemin M. Akay, Yoshua Esquenazi, Nitin Tandon
Scientific Reports. 2020-08-07
1438 citations
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
Roger Stupp, Sophie Taillibert, Andrew A. Kanner, William L. Read, David M. Steinberg
JAMA. 2017-12-19
56 citations
Telomerase Activity in Human Gliomas
Siyuan Le, Jay-Jiguang Zhu, Douglas C. Anthony, Carol W. Greider, Peter McL. Black
Neurosurgery. 1998-05-01

Press Mentions

Cancer-Killing Virus plus Immunotherapy Boosts Survival in Aggressive Brain CancerMay 19th, 2023
'He's My Miracle': Houston Man with Brain Tumor Given Two Months to Live, but He's Still Alive Six Years LaterJuly 18th, 2022

Professional Memberships

American Academy of Neurology - AAN
Member
American Society of Clinical Oncology - ASCO
Member
Society of Neuro-oncology
Member

Other Languages

Chinese (Mandarin)